Colorectal Cancer — A Roundtable Discussion on the Use of Molecular Residual Disease Analysis

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics:

• Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00)
• Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44)
• Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16)
• Clinical Investigator Survey Results (56:06)
• Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05)
• Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06)
• Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57)
• Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54)
• Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17)
• Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05)
• Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05)

CME information and select publications